AIM: In 80-85% of cases, congenital hypothyroidism is associated with thyroid dysgenesis (TD), but only in a small percentage of cases mutations in thyroid transcription factors (NKX2.1, PAX8, FOXE1, and NKX2.5) have been associated with the disease. Several studies demonstrated that the activity of the transcription factors can be modulated by the interaction with other proteins, such as coactivators and co-repressors, and TAZ (transcriptional co-activator with PDZ-binding motif or WWTR1) is a co-activator interacting with both NKX2.1 and PAX8. In the present study we investigate the role of TAZ in the pathogenesis of TD. MATERIAL AND METHODS: By Single Stranded Conformational Polymorphism, we screened the entire TAZ coding sequence for mutations in 96 patients with TD and in 96 normal controls. RESULTS: No mutations were found in patients and controls, but we found several polymorphisms in both groups. No significant differences could be demonstrated in the prevalence of the mutations between patients and controls. CONCLUSIONS: Our data indicate that TAZ mutations are not a cause of TD in the series of patients studied.
AIM: In 80-85% of cases, congenital hypothyroidism is associated with thyroid dysgenesis (TD), but only in a small percentage of cases mutations in thyroid transcription factors (NKX2.1, PAX8, FOXE1, and NKX2.5) have been associated with the disease. Several studies demonstrated that the activity of the transcription factors can be modulated by the interaction with other proteins, such as coactivators and co-repressors, and TAZ (transcriptional co-activator with PDZ-binding motif or WWTR1) is a co-activator interacting with both NKX2.1 and PAX8. In the present study we investigate the role of TAZ in the pathogenesis of TD. MATERIAL AND METHODS: By Single Stranded Conformational Polymorphism, we screened the entire TAZ coding sequence for mutations in 96 patients with TD and in 96 normal controls. RESULTS: No mutations were found in patients and controls, but we found several polymorphisms in both groups. No significant differences could be demonstrated in the prevalence of the mutations between patients and controls. CONCLUSIONS: Our data indicate that TAZ mutations are not a cause of TD in the series of patients studied.
Authors: Claudia R Vianna; Michael Huntgeburth; Roberto Coppari; Cheol Soo Choi; Jiandie Lin; Stefan Krauss; Giorgio Barbatelli; Iphigenia Tzameli; Young-Bum Kim; Saverio Cinti; Gerald I Shulman; Bruce M Spiegelman; Bradford B Lowell Journal: Cell Metab Date: 2006-12 Impact factor: 27.287
Authors: Yu Tian; Robert Kolb; Jeong-Ho Hong; John Carroll; Dawei Li; John You; Roderick Bronson; Michael B Yaffe; Jing Zhou; Thomas Benjamin Journal: Mol Cell Biol Date: 2007-07-16 Impact factor: 4.272
Authors: Bin Wang; Chris K Means; Yanmei Yang; Tatyana Mamonova; Alessandro Bisello; Daniel L Altschuler; John D Scott; Peter A Friedman Journal: J Biol Chem Date: 2012-05-24 Impact factor: 5.157